title: Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
abstract: Background. Inherited BRCA gene mutations convey a high risk for breast and ovarian cancer, but current guidelines limit BRCA mutation testing to women with early-onset cancer and relatives of mutation-positive cases. Benefits and risks of providing this information directly to consumers are unknown. Methods. To assess and quantify emotional and behavioral reactions of consumers to their 23andMe Personal Genome Service(®) report of three BRCA mutations that are common in Ashkenazi Jews, we invited all 136 BRCA1 and BRCA2 mutation-positive individuals in the 23andMe customer database who had chosen to view their BRCA reports to participate in this IRB-approved study. We also invited 160 mutation-negative customers who were matched for age, sex and ancestry. Semi-structured phone interviews were completed for 32 mutation carriers, 16 women and 16 men, and 31 non-carriers. Questions addressed personal and family history of cancer, decision and timing of viewing the BRCA report, recollection of the result, emotional responses, perception of personal cancer risk, information sharing, and actions taken or planned. Results. Eleven women and 14 men had received the unexpected result that they are carriers of a BRCA1 185delAG or 5382insC, or BRCA2 6174delT mutation. None of them reported extreme anxiety and four experienced moderate anxiety that was transitory. Remarkably, five women and six men described their response as neutral. Most carrier women sought medical advice and four underwent risk-reducing procedures after confirmatory mutation testing. Male carriers realized that their test results implied genetic risk for female relatives, and several of them felt considerably burdened by this fact. Sharing mutation information with family members led to screening of at least 30 relatives and identification of 13 additional carriers. Non-carriers did not report inappropriate actions, such as foregoing cancer screening. All but one of the 32 mutation-positive participants appreciated learning their BRCA mutation status. Conclusions. Direct access to BRCA mutation tests, considered a model for high-risk actionable genetic tests of proven clinical utility, provided clear benefits to participants. The unexpected information demonstrated a cascade effect as relatives of newly identified carriers also sought testing and more mutation carriers were identified. Given the absence of evidence for serious emotional distress or inappropriate actions in this subset of mutation-positive customers who agreed to be interviewed for this study, broader screening of Ashkenazi Jewish women for these three BRCA mutations should be considered.
authors: 23andMe, Inc. , Mountain View, CA , USA ; Department of Genetics , Stanford University School of Medicine , Stanford, CA , USA.
authors: Uta
authors: U
authors: Francke
authors: Cheri
authors: C
authors: Dijamco
authors: Amy K
authors: AK
authors: Kiefer
authors: Nicholas
authors: N
authors: Eriksson
authors: Bianca
authors: B
authors: Moiseff
authors: Joyce Y
authors: JY
authors: Tung
authors: Joanna L
authors: JL
authors: Mountain
keywords: Ashkenazi Jewish ancestry; BRCA mutation testing; BRCA mutations; Cascade effect; Direct-access genetic testing; Direct-to-consumer genetic testing; Male BRCA carriers; Personal genomics; Risk-reducing mastectomy; Risk-reducing oophorectomy
references: Breast Cancer Res Treat. 2012 Jun;133(2):735-40
references: 22240989
references: Genet Med. 2012 Apr;14(4):361-84
references: 22436882
references: J Clin Oncol. 2007 Apr 10;25(11):1329-33
references: 17416853
references: Clin Genet. 2005 Jun;67(6):492-502
references: 15857416
references: N Engl J Med. 2009 Jul 16;361(3):245-54
references: 19605829
references: J Clin Oncol. 2010 Feb 10;28(5):893-901
references: 20065170
references: Hered Cancer Clin Pract. 2011 Jun 28;9(1):3
references: 21711529
references: Genet Med. 2013 Jan;15(1):36-44
references: 22995991
references: N Engl J Med. 2010 Sep 16;363(12):1100-1
references: 20843242
references: J Clin Oncol. 2003 Jun 15;21(12):2397-406
references: 12692171
references: Clin Genet. 2010 Apr;77(4):342-9
references: 20059483
references: J Clin Oncol. 2010 Jan 20;28(3):387-91
references: 20008623
references: Clin Genet. 2012 Sep;82(3):210-8
references: 22372614
references: Health Psychol. 2009 Jul;28(4):510-8
references: 19594276
references: N Engl J Med. 2007 Jul 12;357(2):154-62
references: 17625127
references: JAMA. 2008 Dec 10;300(22):2669-71
references: 19066388
references: Genet Med. 2011 Jun;13(6):499-504
references: 21558861
references: J Genet Couns. 2012 Jun;21(3):386-91
references: 22223063
references: Cancer. 2012 Jan 15;118(2):510-7
references: 21717445
references: Cancer. 2003 Aug 1;98(3):597-602
references: 12879478
references: J Genet Couns. 2012 Jun;21(3):399-401
references: 22271377
references: JAMA. 2010 Sep 1;304(9):967-75
references: 20810374
references: Genet Med. 2012 Apr;14(4):405-10
references: 22422049
references: Br J Cancer. 1999 Mar;79(7-8):1302-3
references: 10098775
references: J Med Genet. 2002 Aug;39(8):611-4
references: 12161607
references: J Biosci. 2009 Sep;34(3):415-22
references: 19805903
references: J Genet Couns. 2007 Jun;16(3):241-60
references: 17508274
references: Fam Cancer. 2003;2(3-4):153-8
references: 14707526
references: N Engl J Med. 2011 Feb 10;364(6):524-34
references: 21226570
references: Ann Oncol. 2003 Apr;14(4):549-53
references: 12649099
references: J Genet Couns. 2012 Jun;21(3):413-22
references: 22278220
references: J Genet Couns. 2010 Aug;19(4):330-42
references: 20379768